Meet the startup on the new frontier of synthetic CBD…
The CBD industry is driven by unstoppable consumer demand. It’s not going anywhere.
In fact, in just 3 short years, CBD sales will be up 3,622%, according to projections from industry experts.
And for cannabis investors, the potential to profit from the CBD revolution is just too good to pass up.
Millions of people who use CBD can tell you how it has helped them with everything from recovering after an intense workout to reducing anxiety after a long day of work.
Its anti-inflammatory properties have even propelled CBD-infused beauty products into a major $1 billion market segment.
But as of right now, the claims surrounding CBD’s healing potential are largely anecdotal accounts. The CBD industry needs hard evidence.
So, when Executive Director Don Yocham found out about a company with a team of chemists working to bring science and data to the CBD industry, he knew he had to sit down with the founder.
Exclusive Interview With Nalu Bio
Don recently had the opportunity to pick the brain of Caitlyn Krebs, the founder and CEO of Nalu Bio – a new kind of CBD startup that’s working to take CBD from a pseudoscience to a real drug through clinical studies.
Caitlyn has an impressive background in the health care and biotech spaces, having worked at the forefront of advances in diabetes prevention, Alzheimer’s prevention, and early cancer detection, just to name a few.
She set her sights on CBD because, like our forward-thinking community here at the National Institute for Cannabis Investors, she believes it’s the new frontier of health and wellness.
And the CBD her team is creating is unique. Rather than being derived from hemp, Nalu Bio is developing it in a lab through chemical synthesis.
“We’re translating what pharma has done for hundreds of years to the CBD and cannabis industry.”
– Caitlyn Krebs, Founder and CEO of Nalu Bio
They believe they can produce this synthetic CBD for a fraction of the cost of hemp-derived CBD, and their goal is to then bring their product to the shelves of popular retailers like CVS and Walgreens.
In this fascinating interview, you’ll get to see for yourself how this startup is not only creating a product that’s pure and scalable, but one that’s backed by science.
Whether it’s synthetic or hemp-derived, the fact of the matter is that CBD is here to stay.
Learn how to claim your stake in the multibillion-dollar CBD revolution right here.
cbdMD has one of the most impressive lists of athlete ambassadors on the market right now. And with the convergence of the sports recovery and CBD markets, Don wanted to hear from CEO Marty Sumichrast directly about the company’s branding strategy and how it’s adapting its approach during the coronavirus. Watch the exclusive interview…
10 responses to “How a New CBD Startup Is Creating Pure, Scalable, Science-Backed CBD”
May 12 2020